Who Won the 2026 Nobel Prize in Medicine? Optogenetics Pioneers Deisseroth, Hegemann and Nagel Honored

Stockholm — The 2026 Nobel Prize in Physiology or Medicine has been awarded jointly to Karl Deisseroth of the United States, Peter Hegemann of Germany and Georg Nagel of Germany for discoveries that led to optogenetics, a technology that uses light to control selected nerve cells and has reshaped neuroscience research.

The Nobel Assembly at Sweden’s Karolinska Institutet on Monday awarded the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann and Georg Nagel for foundational discoveries behind optogenetics, a method that lets scientists use light to activate or silence precisely selected cells in the nervous system.

The official citation recognizes the trio “for their discoveries concerning light-gated ion channels and optogenetics.” Their work turned an unusual light-sensitive protein from algae into a tool that has allowed scientists to probe how specific neural circuits contribute to memories, feelings and behavior in living animals.

Deisseroth is affiliated with the Howard Hughes Medical Institute and Stanford University in the United States. Hegemann is a Hertie senior professor of neuroscience at Humboldt University of Berlin, while Nagel is a professor of molecular plant physiology at the University of Würzburg.

From algae to neural circuits

At the center of the prize is channelrhodopsin, a protein found in Chlamydomonas, a microscopic green alga that can move toward light.

Hegemann and Nagel’s research established that channelrhodopsins act as ion channels that open in response to light. When illuminated, the proteins allow charged particles to flow into a cell, producing an electrical signal. The researchers showed that the proteins could make other types of cells light-sensitive when the relevant genes were introduced.

That discovery created the essential molecular component for optogenetics. The technique combines genetics and optics: scientists introduce genes encoding light-responsive proteins into a targeted population of cells, then use light of a defined wavelength to influence those cells’ activity.

Deisseroth, a physician-scientist and neuroscientist at Stanford, took the next decisive step. His group introduced the gene for channelrhodopsin-2 into rat neurons grown in the laboratory and showed in 2005 that pulses of blue light could trigger nerve signals.

Two years later, his team demonstrated light-based control of selected neurons in the brains of living mice, using a thin optical fiber to deliver light to targeted brain areas. The experiments established a practical way to test causal links between particular neural circuits and behavior rather than merely observing which brain regions become active.

“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, said in the Nobel announcement.

Why the discovery matters

The human brain contains roughly 90 billion nerve cells and an extraordinary number of connections. Before optogenetics, scientists could observe brain activity or stimulate larger areas electrically, but it was harder to manipulate narrowly defined cell populations with the speed and precision needed to establish whether a circuit directly caused a behavior or biological response.

Optogenetics changed that experimental landscape. It enables investigators to target specific types of neurons, control their activity on rapid timescales and examine the resulting effects in living organisms. The Nobel Assembly said the method has helped researchers identify neural circuits involved in such functions as pain, social behavior, thirst, feeding, reward, attention, sleep and circadian rhythms.

The award also underscores the importance of basic research that crosses disciplinary boundaries. A question about how a single-celled alga senses and moves toward light ultimately yielded a central technology in modern neuroscience.

The research has implications beyond the brain. According to the Nobel Assembly’s background materials, optogenetic approaches have helped researchers study interactions between the nervous system and cells elsewhere in the body, including in the heart and gut.

Still, the Nobel-recognized achievement is principally a research platform, not a broadly established therapy. Optogenetics usually requires delivering genetic material that makes cells responsive to light and then getting light to the relevant tissue, challenges that can be particularly significant in the human brain.

Clinical prospects remain early

Scientists are exploring whether the approach could eventually support treatments for neurological, psychiatric and sensory disorders. The Nobel Assembly said optogenetics has expanded research into conditions including depression, anxiety, schizophrenia, Alzheimer’s disease and Parkinson’s disease.

But understanding disease-related circuits and translating a laboratory method into a safe, effective treatment are separate steps. The Nobel materials describe clinical efforts to restore limited vision in people with retinitis pigmentosa, an inherited condition that damages the retina’s light-sensing cells. In one reported approach, researchers inserted a channelrhodopsin-like protein into retinal cells and used specialized light-emitting glasses; the Nobel Assembly said a blind participant was able to distinguish and grasp objects on a table.

The same materials note potential future applications in hearing technology. Researchers hope that optogenetic approaches could one day enable cochlear implants to stimulate the auditory nerve more precisely than conventional electrical systems, though such applications remain under development.

The award does not amount to a declaration that optogenetics has solved neurological disease. Rather, it recognizes the fundamental discoveries that supplied researchers with a much more exact way to investigate the living nervous system.

What is confirmed, and what is not

The Nobel Assembly has confirmed that the prize will be shared among Deisseroth, Hegemann and Nagel and that the award concerns their discoveries involving light-gated ion channels and optogenetics. The prize amount is 12 million Swedish kronor, split equally.

It is also established that channelrhodopsins came from research into Chlamydomonas, that Hegemann and Nagel characterized the proteins’ light-gated properties, and that Deisseroth’s work helped turn the discovery into a neural-control method.

What remains uncertain is the timeline and extent of future clinical adoption. The Nobel materials cite ongoing research and early clinical efforts, but they do not claim that optogenetics has yet become a routine treatment for brain disorders. Claims about eventual therapies will require evidence from rigorously designed clinical trials and regulatory review.

Nobel week begins

The physiology or medicine prize traditionally opens the annual Nobel announcements. The 2026 schedule calls for the physics prize on Tuesday, chemistry on Wednesday, literature on Thursday, peace on Friday and the Sveriges Riksbank Prize in Economic Sciences on Oct. 12.

The laureates are expected to receive their Nobel awards in Stockholm on Dec. 10, the anniversary of Alfred Nobel’s death. The Nobel prizes have been awarded since 1901, with the economics prize added in 1968 by Sweden’s central bank.

Last year’s medicine prize went to Mary E. Brunkow, Frederick J. Ramsdell and Shimon Sakaguchi for discoveries concerning peripheral immune tolerance, research that clarified how the immune system avoids attacking healthy tissue.

For this year’s laureates, the award recognizes a scientific chain running from a light-seeking alga to experiments that allow researchers to switch individual nerve circuits on and off, and, in doing so, investigate one of biology’s most complex systems with new precision.